Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults Age 56 Years and Older
Conditions
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined
Locations
36
United States
Chandler, Arizona, United States
Anaheim, California, United States
San Diego, California, United States
Waterbury, Connecticut, United States
Clearwater, Florida, United States
DeLand, Florida, United States
Start Date
July 15, 2016
Primary Completion Date
February 13, 2017
Completion Date
February 13, 2017
Last Updated
April 5, 2022
NCT07203755
NCT05590455
NCT05383742
NCT05777499
NCT06811025
NCT06465420
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions